Q3 order intake rose 8%, comparable sales grew approximately 3%, and adjusted EBITDA margin increased by 70 basis points to 13%. Philips generated 384 million euros of free cash flow and recorded a 288 million euros Respironics provision.
PHG · Koninklijke Philips NV
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Royal Philips reported Q3 comparable sales growth of 3% and order intake growth of 8%. Respironics reached agreement in principle with the US Department of Justice, triggering a EUR 288 million provision; the 2026 outlook was reiterated.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PHG
this stock
Koninklijke Philips NV
|
$29.22B | +10.4% | — | — | 0.2% |
|
ABT
Abbott Laboratories
|
$181.35B | -16.4% | +5.7% | 39.1 | 1.1% |
|
MDT
Medtronic plc
|
$130.88B | +6.5% | +8.4% | 25.2 | 1.8% |
|
SYK
Stryker Corp
|
$120.88B | -9.7% | +11.2% | 33.8 | 1.7% |
|
BSX
Boston Scientific Corp
|
$62.37B | -54.9% | +12.5% | 18.2 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 3, 2026
- This year
- 11
Royal Philips reported Q3 comparable sales growth of 3% and order intake growth of 8%. Respironics reached agreement in principle with the US Department of Justice, triggering a EUR 288 million provision; the 2026 outlook was reiterated.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PHG | -1.7% | +15.0% | +13.0% | +11.0% | +10.4% |
| SPY | -2.3% | -4.8% | -2.9% | -3.1% | +7.4% |
| vs SPY | +0.6% | +19.7% | +16.0% | +14.1% | +3.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.